Therapeutic outcomes in AIDS-associated kaposi's sarcoma patients on antiretroviral therapy treated with chemotherapy at two tertiary hospitals in Lusaka, Zambia

Watson Mtonga, Aaron Mujajati, Derick Munkombwe, Aubrey Kalungia, Lungwani Tyson Muungo, John T West, Charles Wood, Owen Ngalamika

Research output: Contribution to journalArticle

Abstract

The incidence of HIV-associated Kaposi’s sarcoma (KS) remains high in Zambia in the antiretroviral therapy era. The most efficacious treatment regimen for KS has yet to be established. In both developed and developing countries, treatment regimens have had limited efficacy. Late presentation in Africa affects therapeutic outcomes. Objective: The aim of this study was to determine therapeutic outcomes of epidemic KS patients on combination antiretroviral therapy (cART) after completion of six cycles of Adriamycin, Bleomycin, and Vincristine (ABV) chemotherapy. Methods: This was a descriptive cross-sectional study. Study participants were drawn from a study database of confirmed incident KS patients seen at the Skin Clinic of the University Teaching Hospitals (UTH) during the period between August, 2015 and September, 2016. Results: Of the 38 successfully recruited study participants, a complete response was documented in 18 (47%) after 6 cycles of ABV whereas 20 (53%) experienced a partial response. KS recurrence was observed in 8 (44%) of the individuals that experienced an initial complete response. At the time of the study, clinical assessment revealed that KS lesions had completely regressed in 21 (55%) of all the patients. Conclusion: ABV chemotherapy appears ineffective in long-term resolution of epidemic KS patients on ART. Recurrence rates are high after chemotherapy in patients that experience initially favorable responses to treatment. There is a need to diagnose KS earlier, and to develop more efficacious treatment options in order to reduce recurrence rates for epidemic KS.

Original languageEnglish (US)
Pages (from-to)231-236
Number of pages6
JournalCurrent HIV research
Volume16
Issue number3
DOIs
StatePublished - Jan 1 2018

Fingerprint

Zambia
Kaposi's Sarcoma
Tertiary Care Centers
Acquired Immunodeficiency Syndrome
Drug Therapy
Bleomycin
Vincristine
Doxorubicin
Therapeutics
Recurrence
Time and Motion Studies
Developed Countries
Teaching Hospitals
Developing Countries
Cross-Sectional Studies
HIV
Databases
Skin

Keywords

  • Chemotherapy
  • HIV-associated
  • Kaposi’s sarcoma
  • Outcomes
  • Recurrence
  • Treatment

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Therapeutic outcomes in AIDS-associated kaposi's sarcoma patients on antiretroviral therapy treated with chemotherapy at two tertiary hospitals in Lusaka, Zambia. / Mtonga, Watson; Mujajati, Aaron; Munkombwe, Derick; Kalungia, Aubrey; Muungo, Lungwani Tyson; West, John T; Wood, Charles; Ngalamika, Owen.

In: Current HIV research, Vol. 16, No. 3, 01.01.2018, p. 231-236.

Research output: Contribution to journalArticle

Mtonga, Watson ; Mujajati, Aaron ; Munkombwe, Derick ; Kalungia, Aubrey ; Muungo, Lungwani Tyson ; West, John T ; Wood, Charles ; Ngalamika, Owen. / Therapeutic outcomes in AIDS-associated kaposi's sarcoma patients on antiretroviral therapy treated with chemotherapy at two tertiary hospitals in Lusaka, Zambia. In: Current HIV research. 2018 ; Vol. 16, No. 3. pp. 231-236.
@article{961293d8c7084af094d8ae9db8b4232c,
title = "Therapeutic outcomes in AIDS-associated kaposi's sarcoma patients on antiretroviral therapy treated with chemotherapy at two tertiary hospitals in Lusaka, Zambia",
abstract = "The incidence of HIV-associated Kaposi’s sarcoma (KS) remains high in Zambia in the antiretroviral therapy era. The most efficacious treatment regimen for KS has yet to be established. In both developed and developing countries, treatment regimens have had limited efficacy. Late presentation in Africa affects therapeutic outcomes. Objective: The aim of this study was to determine therapeutic outcomes of epidemic KS patients on combination antiretroviral therapy (cART) after completion of six cycles of Adriamycin, Bleomycin, and Vincristine (ABV) chemotherapy. Methods: This was a descriptive cross-sectional study. Study participants were drawn from a study database of confirmed incident KS patients seen at the Skin Clinic of the University Teaching Hospitals (UTH) during the period between August, 2015 and September, 2016. Results: Of the 38 successfully recruited study participants, a complete response was documented in 18 (47{\%}) after 6 cycles of ABV whereas 20 (53{\%}) experienced a partial response. KS recurrence was observed in 8 (44{\%}) of the individuals that experienced an initial complete response. At the time of the study, clinical assessment revealed that KS lesions had completely regressed in 21 (55{\%}) of all the patients. Conclusion: ABV chemotherapy appears ineffective in long-term resolution of epidemic KS patients on ART. Recurrence rates are high after chemotherapy in patients that experience initially favorable responses to treatment. There is a need to diagnose KS earlier, and to develop more efficacious treatment options in order to reduce recurrence rates for epidemic KS.",
keywords = "Chemotherapy, HIV-associated, Kaposi’s sarcoma, Outcomes, Recurrence, Treatment",
author = "Watson Mtonga and Aaron Mujajati and Derick Munkombwe and Aubrey Kalungia and Muungo, {Lungwani Tyson} and West, {John T} and Charles Wood and Owen Ngalamika",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1570162X16666180711103610",
language = "English (US)",
volume = "16",
pages = "231--236",
journal = "Current HIV Research",
issn = "1570-162X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Therapeutic outcomes in AIDS-associated kaposi's sarcoma patients on antiretroviral therapy treated with chemotherapy at two tertiary hospitals in Lusaka, Zambia

AU - Mtonga, Watson

AU - Mujajati, Aaron

AU - Munkombwe, Derick

AU - Kalungia, Aubrey

AU - Muungo, Lungwani Tyson

AU - West, John T

AU - Wood, Charles

AU - Ngalamika, Owen

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The incidence of HIV-associated Kaposi’s sarcoma (KS) remains high in Zambia in the antiretroviral therapy era. The most efficacious treatment regimen for KS has yet to be established. In both developed and developing countries, treatment regimens have had limited efficacy. Late presentation in Africa affects therapeutic outcomes. Objective: The aim of this study was to determine therapeutic outcomes of epidemic KS patients on combination antiretroviral therapy (cART) after completion of six cycles of Adriamycin, Bleomycin, and Vincristine (ABV) chemotherapy. Methods: This was a descriptive cross-sectional study. Study participants were drawn from a study database of confirmed incident KS patients seen at the Skin Clinic of the University Teaching Hospitals (UTH) during the period between August, 2015 and September, 2016. Results: Of the 38 successfully recruited study participants, a complete response was documented in 18 (47%) after 6 cycles of ABV whereas 20 (53%) experienced a partial response. KS recurrence was observed in 8 (44%) of the individuals that experienced an initial complete response. At the time of the study, clinical assessment revealed that KS lesions had completely regressed in 21 (55%) of all the patients. Conclusion: ABV chemotherapy appears ineffective in long-term resolution of epidemic KS patients on ART. Recurrence rates are high after chemotherapy in patients that experience initially favorable responses to treatment. There is a need to diagnose KS earlier, and to develop more efficacious treatment options in order to reduce recurrence rates for epidemic KS.

AB - The incidence of HIV-associated Kaposi’s sarcoma (KS) remains high in Zambia in the antiretroviral therapy era. The most efficacious treatment regimen for KS has yet to be established. In both developed and developing countries, treatment regimens have had limited efficacy. Late presentation in Africa affects therapeutic outcomes. Objective: The aim of this study was to determine therapeutic outcomes of epidemic KS patients on combination antiretroviral therapy (cART) after completion of six cycles of Adriamycin, Bleomycin, and Vincristine (ABV) chemotherapy. Methods: This was a descriptive cross-sectional study. Study participants were drawn from a study database of confirmed incident KS patients seen at the Skin Clinic of the University Teaching Hospitals (UTH) during the period between August, 2015 and September, 2016. Results: Of the 38 successfully recruited study participants, a complete response was documented in 18 (47%) after 6 cycles of ABV whereas 20 (53%) experienced a partial response. KS recurrence was observed in 8 (44%) of the individuals that experienced an initial complete response. At the time of the study, clinical assessment revealed that KS lesions had completely regressed in 21 (55%) of all the patients. Conclusion: ABV chemotherapy appears ineffective in long-term resolution of epidemic KS patients on ART. Recurrence rates are high after chemotherapy in patients that experience initially favorable responses to treatment. There is a need to diagnose KS earlier, and to develop more efficacious treatment options in order to reduce recurrence rates for epidemic KS.

KW - Chemotherapy

KW - HIV-associated

KW - Kaposi’s sarcoma

KW - Outcomes

KW - Recurrence

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85055663806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055663806&partnerID=8YFLogxK

U2 - 10.2174/1570162X16666180711103610

DO - 10.2174/1570162X16666180711103610

M3 - Article

C2 - 29992888

AN - SCOPUS:85055663806

VL - 16

SP - 231

EP - 236

JO - Current HIV Research

JF - Current HIV Research

SN - 1570-162X

IS - 3

ER -